Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 15753389
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The many faces of β-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer

  2004cited by this paper
• Negative Regulation of Prolactin Receptor Stability and Signaling Mediated by SCFβ-TrCP E3 Ubiquitin Ligase

  2004cited by this paper
• Role of F-Box Protein βTrcp1 in Mammary Gland Development and Tumorigenesis

  2004cited by this paper
• Targeting the ubiquitin-proteasome pathway in breast cancer.

  2004cited by this paper
• Development of the Proteasome Inhibitor Velcade™ (Bortezomib)

  2004cited by this paper
• Prophase destruction of Emi1 by the SCF(betaTrCP/Slimb) ubiquitin ligase activates the anaphase promoting complex to allow progression beyond prometaphase.

  2003cited by this paper
• SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor.

  2003cited by this paper
• Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo.

  2003cited by this paper
• When protein destruction runs amok, malignancy is on the loose.

  2003cited by this paper
• Drug discovery in the ubiquitin regulatory pathway.

  2003cited by this paper
• The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

  2003cited by this paper
• Induction of Homologue of Slimb Ubiquitin Ligase Receptor by Mitogen Signaling*

  2002cited by this paper
• Cell cycle regulatory E3 ubiquitin ligases as anticancer targets.

  2002cited by this paper
• Inhibition of HOS expression and activities by Wnt pathway

  2002cited by this paper
• Nuclear transcription factor-kappaB as a target for cancer drug development.

  2002cited by this paper
• The role of ubiquitin-proteasome pathway in oncogenic signaling.

  2002cited by this paper
• Tumor cell death induced by topoisomerase-targeting drugs.

  2001cited by this paper
• Inhibition of homologue of Slimb (HOS) function sensitizes human melanoma cells for apoptosis.

  1999cited by this paper
• HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin.

  1999cited by this paper
• Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.

  1998cited by this paper
• Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis*

  1998cited by this paper
• IkappaB alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-kappaB activation but not tumor necrosis factor-alpha-induced apoptosis.

  1997cited by this paper

• F-box proteins and gastric cancer: an update from functional and regulatory mechanism to therapeutic clinical prospects

  2024cites this paper
• Small molecule and peptide inhibitors of βTrCP and the βTrCP–NRF2 protein–protein interaction

  2023cites this paper
• The crosstalk between ubiquitination and endocrine therapy

  2023influential citation
• Beta-Transducin Repeats-Containing Proteins as an Anticancer Target

  2023cites this paper
• Revealing β-TrCP activity dynamics in live cells with a genetically encoded biosensor

  2022cites this paper
• Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges

  2021cites this paper
• Editorial: Adaptor Protein Regulation in Immune Signalling

  2020cites this paper
• Controlling Nuclear NF-κB Dynamics by β-TrCP—Insights from a Computational Model

  2019cites this paper
• Emerging roles of F-box proteins in cancer drug resistance.

  2019cites this paper
• Targeting IKK and NF-κB for Therapy.

  2017cites this paper
• MicroRNA-182 promotes pancreatic cancer cell proliferation and migration by targeting β-TrCP2.

  2016cites this paper
• A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma

  2015influential citation
• Targeting the ubiquitin pathway for cancer treatment.

  2015cites this paper
• Skp1 in lung cancer: clinical significance and therapeutic efficacy of its small molecule inhibitors

  2015cites this paper
• Expression of β-transducin repeat-containing E3 ubiquitin protein ligase in human glioma and its correlation with prognosis.

  2015cites this paper
• The ubiquitin proteasome system - implications for cell cycle control and the targeted treatment of cancer.

  2014cites this paper
• DNA Damage Regulates UHRF1 Stability via the SCFβ-TrCP E3 Ligase

  2013cites this paper
• The role of the ubiquitin proteasome system in lymphoma.

  2013cites this paper
• Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses

  2013cites this paper
• Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases.

  2012cites this paper
• How is gene transfection able to improve current chemotherapy? The role of combined therapy in cancer treatment.

  2012cites this paper
• Erioflorin Stabilizes the Tumor Suppressor Pdcd4 by Inhibiting Its Interaction with the E3-ligase β-TrCP1

  2012cites this paper
• The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme

  2012cites this paper
• NF‐κB and the link between inflammation and cancer

  2012cites this paper
• βTrCP regulates BMI1 protein turnover via ubiquitination and degradation

  2011influential citation
• SCF E3 ubiquitin ligases as anticancer targets.

  2011cites this paper
• MECHANISMS OF THE DOWNREGULATION OF PROLACTIN RECEPTOR AND THEIR ROLE IN CELL PROLIFERATION

  2010cites this paper
• Cullins and cancer.

  2010cites this paper
• Spermatogenesis rescue in a mouse deficient for the ubiquitin ligase SCF{beta}-TrCP by single substrate depletion.

  2010cites this paper
• β-TrCP Inhibition Reduces Prostate Cancer Cell Growth via Upregulation of the Aryl Hydrocarbon Receptor

  2010cites this paper
• Clusterin Facilitates COMMD1 and I-κB Degradation to Enhance NF-κB Activity in Prostate Cancer Cells

  2010cites this paper
• Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

  2010cites this paper
• The ubiquitin-specific protease USP47 is a novel β-TRCP interactor regulating cell survival

  2010cites this paper
• Genes that modulate the sensitivity for anti-microtubule drug-mediated chemotherapy.

  2010cites this paper
• Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation.

  2010cites this paper
• Impaired turnover of prolactin receptor contributes to transformation of human breast cells.

  2009cites this paper
• Ranking the Relevance of Genes Targeted by Cancer-Associated MiRNAs

  2008cites this paper
• Ligand-independent pathway that controls stability of interferon alpha receptor.

  2008cites this paper
• Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer

  2008cites this paper
• Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor.

  2008cites this paper
• Polyubiquitination of Prolactin Receptor Stimulates Its Internalization, Postinternalization Sorting, and Degradation via the Lysosomal Pathway

  2008cites this paper
• The amplified WWP1 gene is a potential molecular target in breast cancer

  2007cites this paper
• SAG/ROC2 E3 ligase regulates skin carcinogenesis by stage-dependent targeting of c-Jun/AP1 and IκB-α/NF-κB

  2007cites this paper
• E3 ubiquitin ligases as cancer targets and biomarkers.

  2006cites this paper
• Stabilization of prolactin receptor in breast cancer cells

  2006cites this paper
• Acute myelogenous leukemia–derived SMAD4 mutations target the protein to ubiquitin‐proteasome degradation

  2006cites this paper
• Genetic and Expression Aberrations of E3 Ubiquitin Ligases in Human Breast Cancer

  2006cites this paper
• SAG/ROC-SCF beta-TrCP E3 ubiquitin ligase promotes pro-caspase-3 degradation as a mechanism of apoptosis protection.

  2006cites this paper
• Aromatase and breast cancer.

  1998cites this paper